111 related articles for article (PubMed ID: 16027288)
21. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxicity and antiangiogenesis by fibroblast growth factor 2-targeted Ad-TK cancer gene therapy.
Saito K; Khan K; Sosnowski B; Li D; O'Malley BW
Laryngoscope; 2009 Apr; 119(4):665-74. PubMed ID: 19213040
[TBL] [Abstract][Full Text] [Related]
23. Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model.
Terao S; Shirakawa T; Kubo S; Bishunu A; Lee SJ; Goda K; Tsukuda M; Hamada K; Tagawa M; Takenaka A; Fujisawa M; Gotoh A
Urology; 2007 Nov; 70(5):1009-13. PubMed ID: 17919690
[TBL] [Abstract][Full Text] [Related]
24. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
Höti N; Chowdhury W; Hsieh JT; Sachs MD; Lupold SE; Rodriguez R
Mol Ther; 2006 Dec; 14(6):768-78. PubMed ID: 16990052
[TBL] [Abstract][Full Text] [Related]
25. Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells.
Zheng X; Rao XM; Snodgrass CL; McMasters KM; Zhou HS
Cancer Gene Ther; 2006 Jun; 13(6):572-83. PubMed ID: 16341141
[TBL] [Abstract][Full Text] [Related]
26. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells.
Chen L; Chen D; Gong M; Na M; Li L; Wu H; Jiang L; Qian Y; Fang G; Xue X
Cancer Lett; 2009 Nov; 284(2):141-8. PubMed ID: 19447545
[TBL] [Abstract][Full Text] [Related]
27. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
[TBL] [Abstract][Full Text] [Related]
28. eIF4E-targeted suicide gene therapy in a minimal residual mouse model for metastatic soft-tissue head and neck squamous cell carcinoma improves disease-free survival.
Siegele B; Cefalu C; Holm N; Sun G; Tubbs J; Meschonat C; Odaka Y; DeBenedetti A; Ghali GE; Chu Q; Mathis JM; Li BD
J Surg Res; 2008 Jul; 148(1):83-9. PubMed ID: 18570935
[TBL] [Abstract][Full Text] [Related]
29. Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck.
Zhu ZB; Mathis JM; Makhija SK; Lu B; Wang M; Ji S; Rivera AA; Rosenthal EL; Siegal GP; Curiel DT
Int J Oncol; 2007 Nov; 31(5):1213-22. PubMed ID: 17912450
[TBL] [Abstract][Full Text] [Related]
30. Effect of hypoxia on Ad5 infection, transgene expression and replication.
Shen BH; Hermiston TW
Gene Ther; 2005 Jun; 12(11):902-10. PubMed ID: 15690062
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
32. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma.
Hannay J; Davis JJ; Yu D; Liu J; Fang B; Pollock RE; Lev D
Gene Ther; 2007 Apr; 14(8):671-81. PubMed ID: 17287860
[TBL] [Abstract][Full Text] [Related]
33. Adenoviral p53 gene therapy in head and neck squamous cell carcinoma cell lines.
Higuchi Y; Asaumi J; Murakami J; Wakasa T; Inoue T; Kuroda M; Shibuya K; Shigehara H; Kawasaki S; Fukui K; Kishi K; Hiraki Y
Oncol Rep; 2002; 9(6):1233-6. PubMed ID: 12375026
[TBL] [Abstract][Full Text] [Related]
34. A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating Neu expression and preserving Rb function.
Fang L; Huang Y; Hu X; Sun L; He X; Hu H; Pu Y; Cao X; Luo H; Pan S; Gu J; Su C
Chem Biol Interact; 2009 Sep; 181(1):1-7. PubMed ID: 19523934
[TBL] [Abstract][Full Text] [Related]
35. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
36. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
37. A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy.
Leja J; Dzojic H; Gustafson E; Oberg K; Giandomenico V; Essand M
Clin Cancer Res; 2007 Apr; 13(8):2455-62. PubMed ID: 17438105
[TBL] [Abstract][Full Text] [Related]
38. Retinoblastoma RB94 enhances radiation treatment of head and neck squamous cell carcinoma.
Araki K; Ahmad SM; Li G; Bray DA; Saito K; Wang D; Wirtz U; Sreedharan S; O'Malley BW; Li D
Clin Cancer Res; 2008 Jun; 14(11):3514-9. PubMed ID: 18519784
[TBL] [Abstract][Full Text] [Related]
39. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
40. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]